Researchers have used a combination of genetic manipulation and protein structural analysis to determine how the position of 'bulky' amino acids influences the ability of efflux pump inhibitors to ...

Tuberculosis is the world's leading infectious cause of death, killing more than one million people each year. When the antibiotic bedaquiline was introduced in 2012, it was the first new tuberculosis ...

Efflux pumps are membrane-bound transporters that actively expel antibiotics and other toxic compounds from bacterial cells, thereby lowering intracellular drug concentrations below inhibitory levels.

Gram-negative bacteria deploy sophisticated efflux systems to expel chemically diverse antimicrobial agents, underpinning a major form of multidrug resistance. Central to this defence are ...

This "tripartite" protein complex, also known as a multidrug efflux pump, forms a conduit that drains out not only antibiotics but also virulence factors -- i.e., molecules that are produced by the ...

When the antibiotic bedaquiline was introduced in 2012, it was the first new tuberculosis drug in over 40 years. Bedaquiline quickly became the key drug in all standard drug-resistant tuberculosis ...

University of Colorado has divulged efflux pump (bacterial) inhibitors reported to be useful for the treatment of bacterial infections, particularly, gram-negative bacterial infections.

Scientists at The University of Texas at Austin have found a new contributor to antibiotic resistance: bacterial swarms that create ideal breeding grounds to evolve antibiotic resistance, even in the ...

Crestone Inc. and the University of Colorado have reported efflux pump (bacterial) inhibitors potentially useful for the treatment of Gram-negative bacterial infections.

The medical profession is in the midst of losing an arms race. Bacterial antibiotic resistance doesn't just threaten our ability to treat infection but our ability to carry out any treatment where ...